Trial reportThe American journal of psychiatry2018
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Trial report in The American journal of psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 228 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
228 citing papers in PubMed, 11 syntheses or guidelines pooled it, 486 citations in OpenAlex.
- Effectiveness of ketamine-assisted psychotherapy as a treatment for treatment-resistant depression: a systematic review.Psychopharmacology · 2026Pooled it
- Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?European psychiatry : the journal of the Association of European Psychiatrists · 2026Pooled it
- Efficacy and safety of esketamine for pain control after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies.Molecular psychiatry · 2023Pooled it
- Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review.Frontiers in neuroanatomy · 2022Pooled it
- Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.The Cochrane database of systematic reviews · 2021Pooled it
- A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.European child & adolescent psychiatry · 2021Pooled it
- Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.The Cochrane database of systematic reviews · 2021Pooled it
- Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis.Psychopharmacology · 2021Pooled it
- The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Pooled it
- Pairwise common variant meta-analyses of schizophrenia with other psychiatric disorders reveals shared and distinct gene and gene-set associations.Translational psychiatry · 2020Pooled it
- Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.Nature medicine · 2025Trial
- Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: a randomized controlled trial.The international journal of neuropsychopharmacology · 2025Trial
- Opioids diminish the placebo antidepressant response: Observational post hoc findings from a randomized controlled ketamine trial.Journal of affective disorders · 2025Trial
- A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy volunteers.Journal of psychopharmacology (Oxford, England) · 2025Trial
- Effect of Different Doses of Esketamine on Postoperative Recovery in Patients Undergoing Gynecologic Laparoscopic Surgery, a Randomized, Double-Blind, Single-Center Clinical Study.Drug design, development and therapy · 2025Trial
- Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.BMJ (Clinical research ed.) · 2022Trial
- Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.The international journal of neuropsychopharmacology · 2020Trial
- Magnetic Seizure Therapy for Suicidality in Treatment-Resistant Depression.JAMA network open · 2020Trial
- A randomized placebo-controlled PET study of ketamine´s effect on serotoninTranslational psychiatry · 2020Trial
168 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectiveIn addition to N-methyl-d-aspartate receptor antagonism, ketamine produces opioid system activation. The objective of this study was to determine whether opioid receptor antagonism prior to administration of intravenous ketamine attenuates its acute antidepressant or dissociative effects.
methodIn a proposed double-blind crossover study of 30 adults with treatment-resistant depression, the authors performed a planned interim analysis after studying 14 participants, 12 of whom completed both conditions in randomized order: placebo or 50 mg of naltrexone preceding intravenous infusion of 0.5 mg/kg of ketamine. Response was defined as a reduction ≥50% in score on the 17-item Hamilton Depression Rating Scale (HAM-D) score on postinfusion day 1.
resultsIn the interim analysis, seven of 12 adults with treatment-resistant depression met the response criterion during the ketamine plus placebo condition. Reductions in 6-item and 17-item HAM-D scores among participants in the ketamine plus naltrexone condition were significantly lower than those of participants in the ketamine plus placebo condition on postinfusion days 1 and 3. Secondary analysis of all participants who completed the placebo and naltrexone conditions, regardless of the robustness of response to ketamine, showed similar results. There were no differences in ketamine-induced dissociation between conditions. Because naltrexone dramatically blocked the antidepressant but not the dissociative effects of ketamine, the trial was halted at the interim analysis.
conclusionsThe findings suggest that ketamine's acute antidepressant effect requires opioid system activation. The dissociative effects of ketamine are not mediated by the opioid system, and they do not appear sufficient without the opioid effect to produce the acute antidepressant effects of ketamine in adults with treatment-resistant depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.